Angiotensin II Receptor Antagonists (AT-blockers, ARBs, Sartans): Similarities and Differences

Overview

Journal Neth Heart J

Specialty Cardiology & Vascular Diseases

Date 2015 Feb 20

PMID 25696573

Citations 4

Authors

P A van Zwieten

Affiliations

Soon will be listed here.

Abstract

A survey is presented of the registered non-peptidergic angiotensin II receptor antagonists (AT blockers, ARBs, sartans) and their general properties and similarities. Accordingly, their receptor profile, pharmacokinetic and therapeutic applications are discussed. In addition, attention is paid to the individual characteristics of the AT blockers now available. A few components of this category offer additional potentially beneficial properties, owing to their pharmacological or metabolic characteristics. Such additional properties are critically discussed for eprosartan, losartan, telmisartan and valsartan.

Citing Articles

Angiotensin II receptor blockers induce autophagy in prostate cancer cells.

Woo Y, Jung Y Oncol Lett. 2017; 13(5):3579-3585.

PMID: 28529582 PMC: 5431597. DOI: 10.3892/ol.2017.5872.

Drug Interactions in Parkinson's Disease: Safety of Pharmacotherapy for Arterial Hypertension.

Bitner A, Zalewski P, Klawe J, Newton J Drugs Real World Outcomes. 2016; 2(1):1-12.

PMID: 27747611 PMC: 4883207. DOI: 10.1007/s40801-015-0008-7.

Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.

Thomford N, Dzobo K, Chopera D, Wonkam A, Skelton M, Blackhurst D Pharmaceuticals (Basel). 2015; 8(3):637-63.

PMID: 26402689 PMC: 4588186. DOI: 10.3390/ph8030637.

Angiotensin II receptor blockers: a new possible treatment for chronic migraine?.

Disco C, Maggioni F, Zanchin G Neurol Sci. 2015; 36(8):1483-5.

PMID: 25917398 DOI: 10.1007/s10072-015-2217-y.

References

Viberti G, Wheeldon N . Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002; 106(6):672-8. DOI: 10.1161/01.cir.0000024416.33113.0a. View

Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870-8. DOI: 10.1056/NEJMoa011489. View

Pfeffer M, McMurray J, Velazquez E, Rouleau J, Kober L, Maggioni A . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20):1893-906. DOI: 10.1056/NEJMoa032292. View

Barnett A, Bain S, Bouter P, Karlberg B, Madsbad S, Jervell J . Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351(19):1952-61. DOI: 10.1056/NEJMoa042274. View

Dzielak D . Comparative pharmacology of the angiotensin II receptor antagonists. Expert Opin Investig Drugs. 2005; 7(5):741-51. DOI: 10.1517/13543784.7.5.741. View

Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C . Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1993; 265(2):826-34. View

Baan Jr J, Chang P, Vermeij P, Pfaffendorf M, van Zwieten P . Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers. Cardiovasc Res. 1996; 32(5):973-9. View

Andersson O, Neldam S . The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998; 7(1):53-9. DOI: 10.1080/080370598437574. View

Peach M, Dostal D . The angiotensin II receptor and the actions of angiotensin II. J Cardiovasc Pharmacol. 1990; 16 Suppl 4:S25-30. DOI: 10.1097/00005344-199016004-00007. View

10.

Schupp M, Janke J, Clasen R, Unger T, Kintscher U . Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004; 109(17):2054-7. DOI: 10.1161/01.CIR.0000127955.36250.65. View

11.

Acker C, Greenberg A . Angioedema induced by the angiotensin II blocker losartan. N Engl J Med. 1995; 333(23):1572. DOI: 10.1056/nejm199512073332316. View

12.

Hojo Y, Ebata H, Ikeda U, Tsuruya Y, Natsume T, Shimada K . Enhanced spontaneous calcium efflux and decrease of calcium-dependent calcium release from the isolated perfused heart of spontaneously hypertensive rats. J Hypertens. 1992; 10(6):513-20. DOI: 10.1097/00004872-199206000-00003. View

13.

White H . Candesartan and heart failure: the allure of CHARM. Lancet. 2003; 362(9386):754-5. DOI: 10.1016/S0140-6736(03)14294-8. View

14.

Timmermans P, Wong P, Chiu A, Herblin W, Benfield P, Carini D . Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993; 45(2):205-51. View

15.

Goodfriend T, Elliott M, Catt K . Angiotensin receptors and their antagonists. N Engl J Med. 1996; 334(25):1649-54. DOI: 10.1056/NEJM199606203342507. View

16.

West I, Rutherford P, Thomas T . Sodium-lithium countertransport: physiology and function. J Hypertens. 1998; 16(1):3-13. DOI: 10.1097/00004872-199816010-00002. View

17.

Ruilope L, Agabiti Rosei E, Bakris G, Mancia G, Poulter N, Taddei S . Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 2005; 14(4):196-209. DOI: 10.1080/08037050500230227. View

18.

Gradman A, Schmieder R, Lins R, Nussberger J, Chiang Y, Bedigian M . Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111(8):1012-8. DOI: 10.1161/01.CIR.0000156466.02908.ED. View

19.

Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T . Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug,.... J Pharmacol Exp Ther. 1993; 266(1):114-20. View

20.

Nap A, Balt J, Mathy M, van Zwieten P . AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease. Auton Autacoid Pharmacol. 2004; 23(5-6):285-96. DOI: 10.1111/j.1474-8673.2004.00301.x. View